
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | 2026-06-01 | BIENAIME JEAN JACQUES | Director | Purchase | 300 | $223.67 | $67K | 900 | View ↗ | |
| 2026-05-29 | 2026-06-01 | SMITH SCOTT THOMAS | EVP & Chief Financial Officer | Purchase | 250 | $223.32 | $56K | 4,267 | View ↗ | |
| 2026-05-26 | 2026-05-27 | BIENAIME JEAN JACQUES | Director | Purchase | 200 | $236.24 | $47K | 200 | View ↗ | |
| 2026-05-11 | 2026-05-12 | JENSEN FLEMMING STEEN | See Remarks | Sale | 19.5K | $238.49 | $4.64M | 0 | View ↗ |
No financial data available for ASND.
Company may not file with SEC or CIK is unresolved.
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading